Cue Biopharma, Inc. - CUE STOCK NEWS

Welcome to our dedicated page for Cue Biopharma news (Ticker: CUE), a resource for investors and traders seeking the latest updates and insights on Cue Biopharma stock.

Cue Biopharma, Inc. (Nasdaq: CUE) is a pioneering clinical-stage biopharmaceutical company located in Boston, Massachusetts. The company focuses on developing a novel class of injectable biologics designed to selectively engage and modulate disease-specific T cells directly within the patient's body. Cue Biopharma’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), aims to harness the body’s intrinsic immune system as T cell engagers, minimizing the need for ex vivo manipulation and broad systemic immune modulation.

The company's leading clinical programs include CUE-101 and CUE-102. CUE-101 is being evaluated for the treatment of recurrent/metastatic HPV16+ head and neck squamous cell carcinoma both as a monotherapy and in combination with pembrolizumab (KEYTRUDA®). Recent data from Phase 1 trials have shown promising results, including prolonged overall survival and enhanced clinical activity when combined with pembrolizumab.

CUE-102 targets Wilms' Tumor 1 (WT1)-expressing cancers such as colorectal, gastric, and pancreatic cancers. Early Phase 1 trial data for CUE-102 has demonstrated expansion of WT1-specific T cells and favorable tolerability, pointing to potential therapeutic benefits for cancers resistant to traditional treatments.

Additionally, Cue Biopharma is advancing its preclinical program CUE-401 for autoimmune and inflammatory diseases in collaboration with Ono Pharmaceutical. This program aims to redirect virus-specific T cells to deplete B cells in autoimmune conditions.

Financially, Cue Biopharma reported increased collaboration revenue due to its strategic agreement with Ono Pharmaceutical. Despite higher research and development expenses, the company maintains a strong cash position, with approximately $41 million in cash and equivalents expected to fund operations into the first quarter of 2025. The management team, led by CEO Daniel Passeri, continues to focus on strategic corporate objectives, including potential registrational trials for CUE-101 and advancing other therapeutic candidates.

With an experienced leadership and independent Board of Directors, Cue Biopharma is well-positioned to make significant strides in the fields of oncology and autoimmune disease treatment, aiming to deliver transformative therapies for patients while creating value for its shareholders.

02/29/2024 10:00 AM

News

Cue Biopharma’s Lead Clinical Asset, CUE-101, to be Featured at the 2024 Multi-disciplinary Head and Neck Cancers Symposium

Rhea-AI Summary

Cue Biopharma, Inc. (Nasdaq: CUE) announces the presentation of CUE-101 at the 2024 Multi-disciplinary Head and Neck Cancers Symposium. The data highlights include an overall response rate of 47% in first-line patients and a median overall survival of 20.8 months in second-line patients.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.12%

Tags

02/06/2024 08:00 AM

News

Cue Biopharma to Present Corporate Update at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

Cue Biopharma, Inc. (Nasdaq: CUE) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, providing a corporate update on its lead clinical programs, CUE-101 and CUE-102, as well as its lead preclinical autoimmune program partnered with Ono Pharmaceutical. The presentation will also cover market opportunities, competitive positioning, and key forecasted value-driving 2024 milestones.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.46%

Tags

11/22/2023 08:00 AM

News

Cue Biopharma to Present at the JMP Securities Hematology and Oncology Summit

Rhea-AI Summary

Cue Biopharma, Inc. (CUE) will take part in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 5-6, 2023. The company will discuss recent data highlights from its lead clinical programs, CUE-101 and CUE-102, as well as market opportunities, competitive positioning, and anticipated milestones for 2024.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.42%

Tags

11/09/2023 04:05 PM

News

Cue Biopharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Rhea-AI Summary

Cue Biopharma, Inc. (CUE) provided a business and financial update for the third quarter of 2023, presenting positive data from ongoing Phase 1 trials of CUE-101 and CUE-102 at the Society for Immunotherapy of Cancer’s 38th Anniversary Annual Meeting. Financially, the company reported collaboration revenue of approximately $2.1 million for the three months ended September 30, 2023, and $3.7 million for the nine months ended September 30, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

11.33%

Tags

11/07/2023 08:00 AM

News

Cue Biopharma to Present at Three Upcoming Investor Healthcare Conferences in November

Rhea-AI Summary

Cue Biopharma, Inc. (CUE) will participate in three investor conferences this November to provide a corporate overview, including recent data highlights from its lead clinical programs, CUE-101 and CUE-102, representative of the IL-2-based CUE-100 series of selective T cell engagers.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

11/03/2023 12:00 PM

News

Cue Biopharma Presents New Positive Data from Phase 1 Trials of CUE-101 in Head and Neck Cancer and CUE-102 in Wilms’ Tumor 1 Positive Cancers at SITC 2023

Rhea-AI Summary

Cue Biopharma announced positive data from Phase 1 trials of its T cell engagers, CUE-101 and CUE-102, for head and neck cancer and WT1-positive cancers. CUE-101 showed an overall response rate (ORR) of 47% and disease control rate (DCR) of 65% in first-line recurrent/metastatic HNSCC patients. CUE-101 also demonstrated a median overall survival (mOS) of 20.8 months in second-line and beyond patients, compared to historic survival rates of approximately eight months. CUE-102 showed promising results with no dose-limiting toxicities observed and a disease control rate (DCR) of 75%-80% at different doses.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

10.36%

Tags

11/02/2023 08:00 AM

News

Cue Biopharma to Host Business Update Call and Webcast

Rhea-AI Summary

Cue Biopharma, Inc. will host a conference call and webcast on November 9, 2023, to provide a business and clinical update. The company will discuss the progress of its Phase 1 trials for CUE-101 and CUE-102, its IL-2 based biologics for the treatment of head and neck cancer and WT1 expressing cancers. Additional clinical, pipeline, and business updates will also be addressed. Positive data from the clinical programs will be presented at the SITC 2023 Annual Meeting.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

9.9%

Tags

09/27/2023 09:05 AM

News

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Rhea-AI Summary

Cue Biopharma to present two poster presentations at SITC 2023

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

3.39%

Tags

09/26/2023 08:00 AM

News

Cue Biopharma Announces Completion of Patient Enrollment in Phase 1b Study of CUE-101 in Combination with KEYTRUDA®

Rhea-AI Summary

Cue Biopharma completes enrollment of patient expansion cohort for CUE-101 trial in combination with pembrolizumab, demonstrating promising clinical efficacy

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

5.83%

Tags

08/09/2023 04:10 PM

News

Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Rhea-AI Summary

Cue Biopharma provided a business and financial update for Q2 2023. They presented positive data from ongoing Phase 1 trials of CUE-101 for head and neck squamous cell carcinoma. They also initiated enrollment in the highest dose cohort of the CUE-102 Phase 1 trial for gastric, pancreatic, ovarian, and colorectal cancers. The company reported collaboration revenue of $1.4 million and $26,000 for Q2 2023 and 2022, respectively. Research and development expenses were $10.7 million and $9.6 million for Q2 2023 and 2022, respectively. General and administrative expenses were $4.3 million and $3.8 million for Q2 2023 and 2022, respectively. As of June 30, 2023, the company had approximately $57.9 million in cash, cash equivalents, and marketable securities.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-13.26%

Tags

FAQ

What is the current stock price of Cue Biopharma (CUE)?

The current stock price of Cue Biopharma (CUE) is $1.03 as of November 21, 2024.

What is the market cap of Cue Biopharma (CUE)?

The market cap of Cue Biopharma (CUE) is approximately 65.9M.

What is Cue Biopharma's main focus?

Cue Biopharma is focused on developing injectable biologics to selectively engage and modulate disease-specific T cells for treating cancers and autoimmune disorders.

What are CUE-101 and CUE-102?

CUE-101 is being developed for HPV16+ head and neck squamous cell carcinoma, while CUE-102 targets Wilms' Tumor 1 (WT1)-expressing cancers such as colorectal, gastric, and pancreatic cancers.

Where is Cue Biopharma headquartered?

Cue Biopharma is headquartered in Boston, Massachusetts.

What is the Immuno-STAT™ platform?

The Immuno-STAT™ platform is a proprietary technology designed to harness the body’s intrinsic immune system as T cell engagers without the need for ex vivo manipulation or broad systemic immune modulation.

Who are Cue Biopharma’s strategic partners?

Cue Biopharma has partnered with Ono Pharmaceutical for its autoimmune and inflammatory disease program, CUE-401.

What recent financial achievements has Cue Biopharma made?

Cue Biopharma has reported increased collaboration revenue due to its agreement with Ono Pharmaceutical and maintains a strong cash position to fund operations into the first quarter of 2025.

What is the status of the CUE-101 clinical trials?

CUE-101 is in Phase 1 trials for treating HPV16+ head and neck squamous cell carcinoma, both as a monotherapy and in combination with pembrolizumab. Recent data shows prolonged overall survival and enhanced clinical activity.

What does the CUE-102 program aim to achieve?

CUE-102 aims to treat Wilms' Tumor 1 (WT1)-expressing cancers by selectively activating WT1-specific T cells. Early trial data shows expansion of these T cells and favorable tolerability.

What is CUE-401?

CUE-401 is a preclinical program focused on autoimmune and inflammatory diseases, aiming to redirect virus-specific T cells to deplete B cells in autoimmune conditions.